Tam Metin PDF (4158 KB) - Marmara Medical Journal

Ö. TARÇINParaoksonaz-1 ve koroner kalp hastalığıKAYNAKLAR1. Primo-Parmo SL, Sorenson RC, Teiber J, La DuBN. The human serum paraoxonase/arylesterasegene (PON1) is one member of a multigene family.Genomics 1996;33:498-507. doi:10.1006/geno.1996.02252. Mackness MI, Hallam SD, Peard T, Warner S,Walker CH. The separation of sheep and humanserum “A”-esterase activity into the lipoproteinfraction by ultracentrifugation. Comp BiochemPhysiol B 1985;82:675-677.3. Reddy ST, Wadleigh DJ, Grijalva V, et al. Humanparaoxonase-3 is an HDL-associated enzyme withbiological activity similar to paraoxonase-1 proteinbut is not regulated by oxidized lipids. ArteriosclerThromb Vasc Biol 2001;21:542-547.4. Mochizuki H, Scherer SW, Xi T,et al. Human PON2gene at 7q21.3:cloning, multiple mRNA forms, andmissense polymorphisms in the coding sequence.Gene 1998;213:149-157. doi: 10.1016/S0378-1119(98)00193-05. Costa LG, Vitalone A, Cole TB, et al. Modulation ofparaoxonase (PON1) activity. Biochem Pharmacol2005;69: 541-550. doi: 10.1016/j.bcp.22004.08.0276. Mueller RF, Hornung S, Furlong CE, Anderson J,Giblett ER, Motulsky AG. Plasma paraoxonasepolymorphism: a new enzyme assay, population,family, biochemical and linkage studies. Am J HumGenet 1983;35:393-408.7. Cole TB, Jampsa RL, Walter BJ, Arndt TL, RichterRJ, Shih DM, et al. Expression of humanparaoxonase (PON1) during development.Pharmacogenetics 2003;13:1-8. do.:10.1097/00008571-200306000-000078. Augustinsson KB, Barr M. Age variation in plasmaarylesterase activity in children. Clin Chim Acta1963;8:568-573. doi: 10.1016/0009-8981(63)90106-29. Ecobichon DJ, Stephens DS. Perinataldevelopment of human blood esterases. ClinPharmacol Ther 1973;14:41-47.10. de Roos NM, Schouten EG, Scheek LM, van Tol A,Katan MB. Replacement of dietary saturated fatwith trans fat reduces serum paraoxonase activity inhealthy men and women. Metabolism2002;51:1534-1537. doi: 10.1053/meta.2002.3630511. Wallace AJ, Sutherland WHF, Mann JI, WilliamsSM. The effect of meals rich in thermally stressedolive and safflower oils on post-prandial serumparaoxonase activity in patients with diabetes. Eur JClin Nutr 2001;55:951-958.12. Deakin SP, James RW. Genetic and enviromentalfactors modulating serum concentrations andactivities of the antioxidant enzyme paraoxonase-1.Clinical Science 2004;107: 435-447. doi:10.1042/CS2004018713. Mackness MI, Arrol S, Durrington PN. Paraoxonaseprevents accumulation of lipoperoxides in lowdensitylipoprotein. FEBS Lett. 1991;286(1-2):152-154.doi: 10.1016//0014-5793(91)80962-314. Gordon T, Castelli WP, Hjortland MC, Kannel WB,Dawber TR. High density lipoprotein as a protectivefactor against coronary heart disease. TheFramingham Study. Am J Med 1977;62:707-714.doi: 10.1016/00029343(77)90874-915. Kaysen GA. Potential restoration of HDL functionwith apolipoprotein A-I mimetic peptide in end-stagerenal disease. Kidney Int 2009;76(4):359-61. doi:10.1038/ki.2009.20516. Mackness B, Hine D, Liu Y, et al. Paraoxonase-1inhibits oxidized LDL-induced MCP-1 production byendothelial cells. Biochem Biophys Res Commun2004;318:680-683. doi: 10.1016/j.bbrc.2004.04.05617. Ferretti G, Bacchetti T, Marchionni C,et al. Effect ofglycation of high density lipoproteins on theirphysiochemical properties and on paraoxonaseactivity. Acta Diabetol 2001;38:163-169. doi:10.1007/s592-001-8074-z18. Gofman JW, Young W, Tandy R. Ischemic heartdisease, atherosclerosis, and longevity. Circulation1966;34:679-697.19. Rozenberg O, Rosenblat M, Coelman R, et al.Paraoxonase (PON1) deficiency is associated withincreased macrophage oxidative stres: studies inPON1-knockout mice. Free Radic Biol Med2003;34:774-784. doi: 10.1016/S0891-5849(02)01429-620. Navab M, Hama-Levy S, Van Lenten BJ, FonarowGC, Carlinez CJ, Castellani LW. Mildly oxidisedLDL induces an increased apolipoproteinJ/paraoxonase ratio. J Clin Invest 1997;99:2005-2019. doi: 10.1172/JCI11936921. Singh S, Venkatesh S, Verma JS, Verma M,Lellama CO, Goel RC. Paraoxonase(PON1) activityin North west Indian Punjabis with coronary arterydisease. Indian J Med Res 2007;125:783-787.22. Jayakumari N, Thejaseebai G. High prevalence oflow serum paraoxonase1 in subjects with coronaryartery disease. J Clin Biochem Nutr 2009;45(3):278-284. doi: 10.3164/jcbn.08-25523. Kabaroğlu C, Mutaf I, Boydak B, et al. Associationbetween serum paraoxonase activity and oxidativestress in acute coronary syndromes. Acta Cardiol2004;59:606-611.24. Aviram M, Rosenbalt M. Paraoxonases andcardiovascular diseases: pharmacological andnutritional influences. Curr Opin Lipidol2005;16:393-399.25. Suehiro T, Nakanchi Y, Yammamoto M, Arii K, ItohH, Hamashige N, et al. Paraoxonase genepolymorphism in Japanese subjects with coronaryheart disease. Br J Pharmacol 1996;57:69-73. doi:10.1016/S0167-5273(96)02779-926. Antikainen M, Mutomaki S, Syvanne M, Pahlman R,Tanvanainen E, Jauhianen M, et al. The Gln Arg191 polymorphism of human paraoxonase gene(HUMPONA) is not associated with the risk ofcoronary artery disease in Finns. J Clin Invest1996;98:883-885.27. Mukamal KJ, Pai JK, Jensen MK, Rimm EB.Paraoxonase 1 polymorphisms and risk ofmyocardial infarction in women and men. Circ J2009;73(7):1302-1307. doi: 10.1253/circj.CJ-08-091228. Rios DL, D’Onofrio LO, Cerqueira CC, Bonfim-SilvaR, Carvalho HG, Santos-Filho A, et al. Paraoxonase1 gene polymorphisms in angiographicallyassessed coronary artery disease: evidence forgender interaction among Brazilians. Clin ChemLab Med 2007;45:874-878. doi:10.1515/CCLM.2007.13629. Sanghera DK, Saha N, Aston CE, Kamboh MI.Genetic polymorphism of paraoxonase and the riskof coronary heart disease. Arterioscler ThrombVasc Biol 1997;17:1067-1073.30. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C,CharpentierG, Cohen N, Morabia A, Passa P,Froguel P. Gln-Arg 192 polymorphism of62Marmara Medical Journal 2011; 24 (1):59-63